World Pathology: MolMed S.p.A. – Product Pipeline Review – H2 2011

• Publication date: October 2011

.A. - Product Pipeline Review - H2 2011” provides a detailed overview on the MolMed S.p.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industries Direct’s proprietary databases, MolMed S.p.A.’s corporate website, SEC filings, in...

.A. - Product Pipeline Review - H2 2011” provides a detailed overview on the MolMed S.p.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, MolMed S.p.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from MolMed S.p.A. and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- MolMed S.p.A. - Brief MolMed S.p.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MolMed S.p.A. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MolMed S.p.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MolMed S.p.A.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate MolMed S.p.A.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MolMed S.p.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MolMed S.p.A.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MolMed S.p.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MolMed S.p.A. and identify potential opportunities in those areas.

Pathology Industry in Europe

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
MolMed S.p.A. Snapshot 6
MolMed S.p.A. Overview 6
Key Information 6
Key Facts 6
MolMed S.p.A. – Research and Development Overview 7
Key Therapeutic Areas 7
MolMed S.p.A. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
MolMed S.p.A. – Pipeline Products Glance 12
MolMed S.p.A. – Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
MolMed S.p.A. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
MolMed S.p.A. – Drug Profiles 15
NGR-hTNF 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
NGR-hTNF + Cisplatin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
NGR-hTNF + Cisplatin + Gemcitabine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
NGR-hTNF + Cisplatin + Pemetrexed 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NGR-hTNF + Oxaliplatin + Capecitabine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
TK Cells 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MolMed S.p.A. – Pipeline Analysis 23
MolMed S.p.A. – Pipeline Products by Therapeutic Class 23
MolMed S.p.A. – Pipeline Products by Route of Administration 24
MolMed S.p.A. – Recent Pipeline Updates 25
MolMed S.p.A. - Dormant Projects 28
MolMed S.p.A. – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
August 31, 2010: MolMed Announces Publication Of Phase II Liver Cancer Trial Results In British Journal Of Cancer 30
August 29, 2008: The U.S. Food And Drug Administration Grants Orphan Drug Designation For Molmed’S Investigational Antiumour Drug NGR-hTNF In The Treatment Of Malignant Pleural Mesothelioma 30
October 27, 2010: MolMed Begins Phase II Trial Of NGR-hTNF For Treatment Of Soft Tissue Sarcomas 31
August 25, 2010: MolMed Announces Publication Of Phase II Colorectal Cancer Trial In European Journal Of Cancer 31
September 24, 2009: Update Of Clinical trials Of NGR-hTNF, MolMed’s Anticancer Investigational Biologic Drug 32
September 24, 2009: Update Of Clinical Trials Of NGR-hTNF, MolMed’s Anticancer Investigational Biologic Drug 33
September 24, 2009: Update Of Clinical Trials Of NGR-hTNF, Molmed’S Anticancer Investigational Biologic Drug 33
May 24, 2010: MolMed Receives FDA Clearance To Initiate Phase III Trial Of NGR-hTNF In Mesothelioma 34
February 24, 2011: MolMed Expands Phase III Trial Of NGR-hTNF For Treatment Of Mesothelioma In Other European Countries 34
October 22, 2009: Molmed Wins The Patent Litigation Related To TK Therapy 35
September 22, 2010: MolMed Announces Positive Results Of Phase I/II NGR-hTNF Trial In Combination Therapy For Treatment Of Colorectal Cancer 36
January 22, 2008: Molmed Gets Regulatory Approval To Start A Phase III Trial In Italy Of Its TK Therapy For High Risk Acute Leukemia 36
April 21, 2010: Results Of Phase II Trial Of NGR-hTNF In Mesothelioma Published By The Journal Of Clinical Oncology 37
September 20, 2007: MolMed Announces Publication Of A Paper On The Antitumour Activity Of Its Cancer Therapeutic Vaccination Approach In The Journal Of Clinical Investigation 37
April 20, 2010: MolMed Starts Phase III Trial Of NGR-hTNF In Mesothelioma 38
August 17, 2011: MolMed's TK Cell Therapy Receives Key European Patent 38
December 13, 2005: Molmed Successfully Completes A Phase I/II Clinical Trial Of TK Therapy In Bone March row Stem Cell Transplantation For High Risk Acute Leukemia 39
November 12, 2009: The European Commission Grants Orphan Drug Designation For MolMed S.p.A.'s NGR-hTNF In the Treatment Of Hepatocellular Carcinoma 39
October 11, 2010: MolMed Reports First Results Of Phase I Trial Of NGR-hTNF In Solid Tumors 40
October 11, 2010: MolMed Reports First Results Of Phase II Lung Cancer Trial Of NGR-hTNF In Combination With Doxorubicin 40
October 11, 2010: MolMed Reports First Results Of Phase II Ovarian Cancer Trial With NGR-hTNF In Combination With Doxorubicin 41
December 07, 2010: MolMed Presents New Data Of TK Cell Based Therapy At Annual Meeting Of ASH 41
October 07, 2008: Molmed’S Partner Takara Bio Inc. Starts A Phase I Trial Of TK For Relapsed Leukaemia In Japan 42
February 06, 2009: MolMed’S Vascular Targeting Agent NGR-hTNF For Solid Tumours Selected For Oral Presentation At Angio 2009 43
January 06, 2011: MolMed Receives IND Clearance From FDA To Conduct Phase III Trial Of TK For High-Risk Leukaemia In US 43
June 05, 2010: MolMed Presents Follow-Up Data From Phase II Trial Of TK Therapy In Leukaemia 44
June 03, 2011: MolMed Reports Long-term Follow Up Data From Phase II Trial In Malignant Pleural Mesothelioma 45
June 03, 2011: MolMed Reports Promising New Data From Phase II Trial Of NGR-hTNF + Cisplatin-Based Chemotherapy In Non-Small Cell Lung Cancer 45
June 03, 2011: MolMed Reports Top-line results From Phase II Trial Of NGR-hTNF + Doxorubicin In Small Cell Lung Cancer 46
Financial Deals Landscape 48
MolMed S.p.A., Deals Summary 48
MolMed S.p.A., Pharmaceuticals & Healthcare, Deal Details 49
Venture Financing 49
MolMed Secures US$ 25 Mln In Venture Financing 49
Partnerships 51
MolMed Concludes a New Deal With Fondazione Telethon 51
MolMed Enters Into Co-Development Agreement With Avecia Biologics 53
MolMed Concludes a New Deal With Immunicon 55
Takara Bio Enters Into Collaboration Agreement With MolMed 56
Licensing Agreements 57
Oxford BioMedica Enters Into Licensing Agreement With MolMed 57
Equity Offering 58
MolMed Completes An Underwritten Rights Offering For US$ 71 Mln 58
MolMed Completes IPO For US$ 82 Mln 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 63
Contact Us 63
Disclaimer 63

List of Tables

MolMed S.p.A. – Pipeline by Therapy Area and Indication, H2 2011 8
MolMed S.p.A. – Pipeline by Stage of Development, H2 2011 9
MolMed S.p.A. – Monotherapy Products in Pipeline, H2 2011 10
MolMed S.p.A. – Combination Treatment Modalities in Pipeline, H2 2011 11
MolMed S.p.A. – Phase III, H2 2011 12
MolMed S.p.A. - Phase II, H2 2011 13
MolMed S.p.A. - Phase I, H2 2011 14
MolMed S.p.A. - Pipeline By Therapeutic Class, H2 2011 23
MolMed S.p.A. – Pipeline By Route of Administration, H2 2011 24
MolMed S.p.A. – Recent Pipeline Updates, H2 2011 25
MolMed S.p.A. - Dormant Developmental Projects, 2010 28
MolMed S.p.A., Deals Summary 48
MolMed Secures US$ 25 Mln In Venture Financing 49
MolMed Concludes a New Deal With Fondazione Telethon 51
MolMed Enters Into Co-Development Agreement With Avecia Biologics 53
MolMed Concludes a New Deal With Immunicon 55
Takara Bio Enters Into Collaboration Agreement With MolMed 56
Oxford BioMedica Enters Into Licensing Agreement With MolMed 57
MolMed Completes An Underwritten Rights Offering For US$ 71 Mln 58
MolMed Completes IPO For US$ 82 Mln 60

List of Figures

MolMed S.p.A. – Pipeline by Therapy Area and Indication, H2 2011 8
MolMed S.p.A. – Pipeline by Stage of Development, H2 2011 9
MolMed S.p.A. – Monotherapy Products in Pipeline, H2 2011 10
MolMed S.p.A. – Combination Treatment Modalities in Pipeline, H2 2011 11
MolMed S.p.A. – Pipeline By Therapeutic Class, H2 2011 23
MolMed S.p.A. – Pipeline By Route of Administration, H2 2011 24